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standardized uptake, infiltrating the ascending 
colon wall, and an osteolytic lesion in the right 
ischial tuberosity (Figure 1D and 1e). 
Given the risk of colon perforation, the patient 
underwent right hemicolectomy. The colonic le‑
sion was identified as an extramedullary plasma‑
cytoma infiltrating the intestinal muscular lay‑
er and focally invading the serosa, without an‑
gioinvasion and with negative surgical margins. 
The patient received radiotherapy to the right 
ischial tuberosity area (50 Gy in 25 fractions), 
which resulted in complete hematologic remission 
(CR). However, PET ‑CT performed a month later 
showed disease progression, with a focal increase 
in 18F ‑fluoro ‑ethyl ‑tyrosine uptake in the ster‑
num, multiple plasmacytomas in the left fourth 
rib, and a persisting osteolytic lesion in the right 
ischial tuberosity (Figure 1F–1H). After achieving 
complete remission with 6 cycles of VTD (bortezo‑
mib, thalidomide, dexamethasone), the patient 
underwent tandem autologous hematopoietic 
A 54 ‑year ‑old woman presented with a pea ‑sized 
solid lump in the sacral region, surrounded by 
a red areola and neither painful nor itchy. A histo‑
pathologic examination showed diffuse infiltrate 
(Figure 1A) composed of atypical plasma cells posi‑
tive for light chains (Figure 1B), CD56, CD138 (Sup‑
plementary material, Figure S1) and negative  for 
CD3, CD20, CD30, CD123, anaplastic lymphoma 
kinase and κ light chains (Supplementary materi‑
al, Figure S2), with a Ki‑67 proliferation index of 
50%. The lesion was identified as an extramedul‑
lary plasmacytoma. Intact immunoglobulins and 
free light chains remained within normal limits, 
and a slightly separated immunoglobulin A zone 
was revealed on immunofixation. No protein was 
detected on urinalysis. Bone marrow trephine bi‑
opsy showed 4% to 5% of dispersed CD138+ plas‑
ma cells with a normal immunohistochemical 
reaction to light (κ/λ) chains (Figure 1C). Fusion 
positron ‑emission tomography–computed tomog‑
raphy (PET ‑CT) revealed a mass with an elevated 
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A B
Figure 1 A, B – histopathologic specimen obtained from the skin lump: A – plasma cells with eosinophilic cytoplasm 
and round nucleus with granular chromatin (hematoxylin and eosin staining, ×400); B – positive immunohistochemical 
reaction to λ light chains (×400). 
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plasmacytoma (SBP), or as a soft tissue mass, 
extramedullary plasmacytoma (EMP).1 EMP may 
develop in any tissue but is primarily found in 
the head and neck region, gastrointestinal tract, 
and lungs.2 SBP is more likely to progress to multi‑
ple myeloma (MM) (3 ‑year progression rate, 60% 
vs 20% for EMP).3 Solitary plasmacytoma can be 
diagnosed if biopsy shows clonal plasma cell infil‑
tration of the lesion, with no or minimal (<10%) 
stem cell transplantation (auto ‑HSCT), followed 
by consolidation VDT ‑PACE therapy (bortezomib, 
dexamethasone, thalidomide, cisplatin, doxoru‑
bicin, cyclophosphamide, etoposide). Currently, 
6 months after auto ‑HSCT, she shows no signs 
of progression.
Solitary plasmacytoma is rare, representing 
less than 5% of plasma cell malignancies. It may 
present as a single bone lesion, solitary bone 
Figure 1  
C – bone marrow trephine 
biopsy; positive 
immunohistochemical 
reaction to CD138 (×400). 
D, e, F, g, H – positron­
­emission tomography–
computed tomography 
scan in axial plane: D – 
a mass (39×13×42 mm) 
infiltrating the ascending 
colon wall; enhanced 
18F ­fluoro ­ethyl ­tyrosine 
uptake (18F ­FET; 
standardized uptake value 
[SUV], 4.12); e – 
an osteolytic lesion 
(diameter, 9 mm) in 
the right ischial tuberosity 
(arrow); enhanced 18F ­FET 
uptake (SUV, 2.9); F – 
focal increase in 18F ­FET 
uptake (11 × 9 mm; SUV, 
3.64) in the sternum, 
at the level of the left 
fourth rib attachment 
(arrow); g – focal 
increase in 18F ­FET uptake 
(SUV, 2.94) in the left 
fourth rib (arrow); H – 
an osteolytic lesion 
(16 × 17 mm) in the right 
ischial tuberosity (arrow); 
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bone marrow involvement, normal skeletal sur‑
vey results, no additional lesions on spinal and 
pelvic magnetic resonance imaging (or computed 
tomography), and no features of end ‑organ dam‑
age.3 Both SBP and EMP are treated locally (frac‑
tionated radiotherapy, 40–50 Gy, with at least 
2 ‑cm margin of normal tissue).1-4 Surgery, fol‑
lowed by radiotherapy, should be considered in pa‑
tients with pathological fractures, large and well‑
‑defined soft tissue lesions, or high risk of com‑
plications.1 Chemotherapy, using the same proto‑
cols as for MM, including high ‑dose chemothera‑
py followed by auto ‑HSCT in younger patients, is 
indicated in refractory disease or relapse.4 How‑
ever, in some countries, especially those in Cen‑
tral and Eastern Europe, inadequate access to 
advanced antimyeloma therapy, including auto‑
‑HSCT, may limit treatment success.5
SuppLeMeNtAry MAteriAL Supplementary ma‑
terial is available with the article at www.pamw.pl.
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